The baseline use of GC at a high dose of ≥10 mg of prednisone equivalent daily for palliative indications is associated with poor outcome in NSCLC patients with PD-1/PD-L1 blockade (18, 19). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.